The Food and Drug Administration (FDA) has approved Lumason (sulfur hexafluoride lipid microsphere; Bracco Diagnostics) for patients whose echocardiograms are difficult to see with ultrasound waves.
Lumason is a contrast agent that consists of microspheres that reflect the sound waves to enhance the image. The physician is able to view the left ventricle chamber and the endocardium more clearly.
The safety and efficacy of Lumason was established in three trials involving 191 patients with suspected cardiac disease whose echocardiograms were difficult to read and interpret. Lumason helped doctors more clearly see the lining of the left ventricle. Across all three studies, independent reviewers were also able to more clearly and completely view inside the patient’s left ventricle.
For more information call (877) 272-2269 or visit BraccoImaging.com.